AU5065198A - Fusion proteins having increased half-lives - Google Patents

Fusion proteins having increased half-lives

Info

Publication number
AU5065198A
AU5065198A AU50651/98A AU5065198A AU5065198A AU 5065198 A AU5065198 A AU 5065198A AU 50651/98 A AU50651/98 A AU 50651/98A AU 5065198 A AU5065198 A AU 5065198A AU 5065198 A AU5065198 A AU 5065198A
Authority
AU
Australia
Prior art keywords
lives
fusion proteins
increased half
increased
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50651/98A
Inventor
Maria Grazia Masucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5065198A publication Critical patent/AU5065198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
AU50651/98A 1996-11-15 1997-11-17 Fusion proteins having increased half-lives Abandoned AU5065198A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3098696P 1996-11-15 1996-11-15
US60030986 1996-11-15
US4894597P 1997-06-25 1997-06-25
US60048945 1997-06-25
PCT/IB1997/001508 WO1998022577A1 (en) 1996-11-15 1997-11-17 Fusion proteins having increased half-lives

Publications (1)

Publication Number Publication Date
AU5065198A true AU5065198A (en) 1998-06-10

Family

ID=26706675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50651/98A Abandoned AU5065198A (en) 1996-11-15 1997-11-17 Fusion proteins having increased half-lives

Country Status (2)

Country Link
AU (1) AU5065198A (en)
WO (1) WO1998022577A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
JP2003510090A (en) * 1999-09-27 2003-03-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 41 human secretory proteins
JP2004525621A (en) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Bifunctional fusion protein having glucocerebrosidase activity
WO2005095443A1 (en) * 2004-03-31 2005-10-13 Cardio Incorporated Drug delivery system using peptide modification
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) † 2006-03-06 2009-04-08 Amunix Inc Genetic packages and uses thereof
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
MX2014005351A (en) 2011-11-03 2014-05-28 Zealand Pharma As Glp-1 receptor agonist peptide gastrin conjugates.
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
LT3564260T (en) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
MX356957B (en) 2012-07-23 2018-06-20 Zealand Pharma As Glucagon analogues.
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
TW202003554A (en) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 Factor VIII-XTEN fusions and uses thereof
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX368436B (en) 2013-10-17 2019-10-03 Zealand Pharma As Acylated glucagon analogues.
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AU2015340586B2 (en) 2014-10-29 2020-04-30 Zealand Pharma A/S GIP agonist compounds and methods
BR112017022009A2 (en) 2015-04-16 2018-07-03 Zealand Pharma A/S ? compound, method of production and synthesis thereof and its use, composition and therapeutic set?
WO2016196249A1 (en) * 2015-05-29 2016-12-08 University Of Utah Research Foundation Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
MA43348A (en) 2015-10-01 2018-08-08 Novo Nordisk As PROTEIN CONJUGATES
BR112019010624A2 (en) 2016-12-09 2019-10-22 Zealand Pharma As double acylated glp-1 / glp-2 agonists and composition
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
WO2019071150A1 (en) 2017-10-06 2019-04-11 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
EP0540263A1 (en) * 1991-10-23 1993-05-05 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
DE4311835A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Method for inhibiting gene transcription
US5833991A (en) * 1995-04-10 1998-11-10 Cobra Therapeutics, Ltd. Glycine-containing sequences conferring invisibility to the immune system
WO1997046573A1 (en) * 1996-06-07 1997-12-11 The University Of Virginia Patent Foundation Method of inhibiting antigen processing, chimeric proteins reflecting this method, and methods of expressing those proteins

Also Published As

Publication number Publication date
WO1998022577A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
AU5065198A (en) Fusion proteins having increased half-lives
AU9482098A (en) Fusion protein systems
GB9718609D0 (en) Fusion protein
AU4382193A (en) BPI-immunoglobulin fusion proteins
AU3562299A (en) Inhibin-hbc fusion protein
AU3827695A (en) Antigen-binding fusion proteins
AU4922497A (en) Interleukin-18-receptor proteins
AU6255096A (en) Pegylated modified proteins
AU7274898A (en) Recombinant antibody-enzyme fusion proteins
AU2842095A (en) High-zirconia fused refractories
AU6721696A (en) Cd44-like protein
AU6873596A (en) Allergen-xcd32 fusion proteins
ZA976666B (en) Fusion polypeptides
AU9798398A (en) Gfp-annexin fusion proteins
AU3804397A (en) Hexameric fusion proteins and uses therefor
AU1985697A (en) Mechanical joint
AU3425197A (en) Fused plug
AU9675198A (en) Counterbored joint
AU2181197A (en) Connecting part
AU6000698A (en) Proteins
AU7229694A (en) Joint
AU5284296A (en) Immune-evading proteins
AU6275098A (en) Novel h-rev 107-like protein
AU4661697A (en) Pfs28 fusion proteins
AU6153396A (en) E6ap-binding proteins